文献速递胃肠外科

膜解剖引导腹腔镜D2淋巴结清扫联合区域完整胃系膜切除治疗局部进展期胃癌的短期与长期效果

The short- and long-term effect of membrane anatomy-guided laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision for locally advanced gastric cancer.
PubMed 文献 · Surg Endosc · 2023-05-08

该回顾性研究纳入599例局部进展期胃癌患者,比较腹腔镜D2+区域完整胃系膜切除(D2+rCME)与传统腹腔镜D2的疗效。D2+rCME组术中出血更少、清扫淋巴结更多、术后排气和进食更早,并发症无增加;3年总生存和无病生存无统计学差异,但D2+rCME组趋势更好,肿瘤沉积阳性患者3年无病生存显著更优。

要点

  • D2+rCME可减少术中出血、增加淋巴结清扫数量并加速术后恢复。
  • D2+rCME不增加术后并发症发生率。
  • 肿瘤沉积阳性患者从D2+rCME中无病生存获益更显著。

核心结论

  • 腹腔镜D2+rCME治疗局部进展期胃癌安全可行,具有出血少、淋巴结清扫多和恢复快的优点,不增加并发症。
  • D2+rCME组长期疗效呈更好趋势,尤其对肿瘤沉积阳性患者3年无病生存有显著获益。

主要发现

  • D2+rCME组术中出血量显著减少(84.20±57.64 ml vs. 148.47±76.97 ml,P<0.001)。
  • D2+rCME组术后首次排气时间缩短(3[2-3]天 vs. 3[3-3]天,P<0.001),首次流质饮食时间缩短(7[7-8]天 vs. 8[7-8]天,P<0.001)。
  • D2+rCME组清扫淋巴结数量更多(43.57±16.52枚 vs. 36.72±13.83枚,P<0.001)。
  • 两组并发症发生率无显著差异(D2+rCME组20.7% vs. D2组19.4%,P>0.05)。
  • 亚组分析中,肿瘤沉积阳性的D2+rCME组患者3年无病生存显著优于D2组(P<0.05)。

临床怎么用

  • 对于局部进展期胃癌,腹腔镜D2+rCME可作为安全可行的术式选择,有助于减少出血、增加淋巴结清扫和加速康复。
  • 肿瘤沉积阳性患者可能从D2+rCME中获长期生存获益,术式选择时可参考肿瘤沉积状态。

局限性

  • 本研究为单中心回顾性分析,可能存在选择偏倚。
  • 3年总生存和无病生存无统计学差异,长期疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Retrospectively analyzed the short- and long-term efficacy between laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision (D2 + rCME) and traditional laparoscopic D2 in the treatment of patients with locally advanced gastric cancer (LAGC), in order to obtain more evidence for D2 + rCME gastrectomy. METHODS: A total of 599 LAGC patients who underwent laparoscopy-assisted radical gastrectomy from January 2014 to December 2019, including 367 cases in the D2 + rCME group and 232 cases in the D2 group. Intraoperative and postoperative clinicopathological parameters, postoperative complications and long-term survival in the two groups were statistically analyzed. RESULTS: No significant differences in the positive rate of mesogastric tumor deposits, the number of positive lymph nodes and postoperative length of stay were found between the two groups (P > 0.05). In the D2 + rCME group, intraoperative blood loss was significantly reduced (84.20 ± 57.64 ml vs. 148.47 ± 76.97 ml, P < 0.001), the time to first postoperative flatus and first liquid diet intake were significantly shortened (3[2-3] days vs. 3[3-3] days, P < 0.001; 7[7-8] days vs. 8[7-8] days, P < 0.001), and the number of lymph nodes dissected was greater (43.57 ± 16.52 pieces vs. 36.72 ± 13.83 pieces, P < 0.001). The incidence of complications did not significantly differ between the D2 + rCME group (20.7%) and D2 group (19.4%) (P > 0.05). Although there was no statistically difference in 3-year OS and DFS between the two groups. However, the trend was better in D2 + rCME group. In subgroup analysis, patients with positive tumor deposits (TDs) in the D2 + rCME group had significantly better 3-year DFS compared With D2 group (P < 0.05). CONCLUSION: Laparoscopic D2 + rCME is safe and feasible for the treatment of LAGC and is characterized by less bleeding, greater lymph node dissection and rapid recovery, without increasing postoperative complications. D2 + rCME group showed a better trend of long-term efficacy, especially significant beneficial for LAGC patients who with positive TDs.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Li Z, Wu H, Lin H, et al. The short- and long-term effect of membrane anatomy-guided laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision for locally advanced gastric cancer. Surg Endosc. 2023. PMID: 37157036. doi:10.1007/s00464-023-10089-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。